Efficacy of nirsevimab for the prevention of RSV disease in infants: A systematic review, meta-analysis of randomized controlled trials, and global perspectives on recommendations and unmet needs

Respiratory syncytial virus (RSV) is a major cause of infant hospitalizations, with limited prophylactic options historically available. Nirsevimab, a long-acting monoclonal antibody, has emerged as a promising agent for preventing RSV. To evaluate the efficacy and safety of nirsevimab through a sys...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Pediatrics and neonatology
Hlavní autori:	Lien, Hsin-Chweng, Lien, Chi-Hone, Liu, Tzu-Yu, Weng, Shun-Long, Tai, Yu-Lin, Huang, Ya-Ning, Chi, Hsin, Chiu, Nan-Chang, Yeung, Chun-Yan, Lin, Chien-Yu
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Singapore Elsevier B.V 13.11.2025
Predmet:	Beyfortus Internal Medicine Monoclonal antibody Nirsevimab Passive immunity Pediatrics Respiratory syncytial virus RSV Seasonality Traveller Beyfortus Respiratory syncytial virus RSV Seasonality Passive immunity Monoclonal antibody Traveller Nirsevimab passive immunity monoclonal antibody respiratory syncytial virus traveller seasonality nirsevimab
ISSN:	1875-9572, 2212-1692, 2212-1692
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!